Development asset linked to Gedeon Richter in public FDA and regional records.
pharma · Adolescent Patients (13 to 17 years of age) with Schizophrenia · Adolescent patient (13-17 years of age) with Schizophrenia
Gedeon Richter
Gedeon Richter Plc.
Gedeon Richter drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Budapest, EU HQ
2,763 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Budapest, EU
- Employees
- 2,763
- Programs
- 2
- Drugs
- 5
- Patents
- 0
Gedeon Richter pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Gedeon Richter drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Gedeon Richter in public FDA and regional records.
-
cariprazine
Nervous system (N05)Nervous system (N05) compound in Gedeon Richter's portfolio. Mechanism: Dopamine D3 receptor modulator.
- Mechanism
- Dopamine D3 receptor modulator
-
Development asset linked to Gedeon Richter in public FDA and regional records.
-
Development asset linked to Gedeon Richter in public FDA and regional records.